Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
ConditionPsoriasis Vulgaris
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-50
SponsorAswan University
About this trial
Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.
It is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.
Vaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.
Eligibility criteria
Qualifiers
Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.
Pateints with any age and gender.
Disqualifiers
Pregnancy and lactation.
Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.
Patients with associated inflammatory disease such as infections and autoimmune diseases.
Trial design
Treatments tested in this trial
- vaspin gene polymorphism
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov